Octaplasma (Human Plasma Protein)

Human plasma protein, the active ingredient in Octaplasma, is a plasma‑derived product presented as a sterile liquid for intravenous use. It is used to replace deficient plasma proteins and to manage coagulopathy in patients requiring transfusion therapy. GNH USA supplies Octaplasma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Octaplasma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Octaplasma is employed in clinical situations where plasma protein replacement is required, particularly in disorders of coagulation and massive transfusion protocols. - Massive transfusion: Helps restore coagulation factor levels during extensive blood loss. - Liver disease: Provides necessary clotting factors for patients with hepatic insufficiency. - Surgical bleeding: Assists in controlling bleeding by supplying functional plasma proteins. - Inherited coagulation deficiencies: Supplies missing clotting factors in conditions such as hemophilia A and B. - Trauma care: Supports hemostasis in severe trauma patients.

Adverse reactions to Octaplasma are generally related to its plasma origin and the infusion process.

Common Side Effects: - Fever: Mild temperature elevation during or after infusion. - Chills: Transient shaking or feeling cold. - Headache: Mild to moderate discomfort. - Nausea: Stomach upset following administration. - Hypotension: Slight drop in blood pressure. - Allergic rash: Localized skin redness.

Serious or Rare Side Effects: - Anaphylactic reaction: Severe, potentially life‑threatening allergy. - Transfusion‑related acute lung injury (TRALI): Acute respiratory distress. - Hemolytic transfusion reaction: Destruction of red blood cells. - Severe sepsis: Systemic infection from contaminated product. - Disseminated intravascular coagulation (DIC): Abnormal clotting throughout the body.

When using Octaplasma, clinicians should observe specific safety measures to minimize risks. - Verify patient identity: Confirm correct recipient before infusion. - Monitor vital signs: Observe blood pressure, temperature, and respiratory status during administration. - Assess for prior transfusion reactions: Review patient history for allergies or previous adverse events. - Use compatible blood type: Ensure ABO compatibility to avoid hemolysis. - Follow infusion rate guidelines: Administer at recommended speed to reduce reaction risk. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Octaplasma may interact with other blood products or medications that affect coagulation.

Major Interactions (Avoid): - Warfarin: Concurrent use can amplify anticoagulant effect and increase bleeding risk. - Direct oral anticoagulants (DOACs): May potentiate anticoagulation and complicate hemostasis. - High‑dose aspirin or NSAIDs: Combined effect can exacerbate bleeding tendencies.

Moderate Interactions (Monitor Closely): - Heparin: Requires careful monitoring of activated clotting time. - Antifibrinolytics (e.g., tranexamic acid): May alter clot stability when used together. - Immunosuppressants: Potential impact on immune response to plasma proteins.